California Public Employees Retirement System Acquires 181,000 Shares of BioScrip, Inc. (BIOS)
California Public Employees Retirement System raised its position in BioScrip, Inc. (NASDAQ:BIOS) by 37.5% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 663,700 shares of the company’s stock after buying an additional 181,000 shares during the period. California Public Employees Retirement System’s holdings in BioScrip were worth $1,128,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Sheets Smith Wealth Management boosted its stake in shares of BioScrip by 33.9% in the first quarter. Sheets Smith Wealth Management now owns 110,508 shares of the company’s stock worth $188,000 after buying an additional 27,998 shares during the period. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of BioScrip during the first quarter worth $7,422,000. FMR LLC boosted its stake in shares of BioScrip by 3,489.1% in the fourth quarter. FMR LLC now owns 3,529,795 shares of the company’s stock worth $3,671,000 after buying an additional 3,431,447 shares during the period. Teachers Advisors LLC boosted its stake in shares of BioScrip by 14.0% in the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock worth $169,000 after buying an additional 20,000 shares during the period. Finally, Perkins Capital Management Inc. boosted its stake in shares of BioScrip by 4.2% in the first quarter. Perkins Capital Management Inc. now owns 310,500 shares of the company’s stock worth $528,000 after buying an additional 12,500 shares during the period. Institutional investors and hedge funds own 91.16% of the company’s stock.
Shares of BioScrip, Inc. (NASDAQ BIOS) traded up 4.87% during midday trading on Friday, reaching $3.23. 542,118 shares of the company traded hands. The company has a 50 day moving average price of $2.82 and a 200 day moving average price of $2.02. The company’s market capitalization is $411.74 million. BioScrip, Inc. has a 1-year low of $0.98 and a 1-year high of $3.43.
BioScrip (NASDAQ:BIOS) last released its earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The business had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. The company’s revenue was down 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.14) earnings per share. On average, analysts expect that BioScrip, Inc. will post ($0.55) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/california-public-employees-retirement-system-acquires-181000-shares-of-bioscrip-inc-bios/1475086.html.
BIOS has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. ValuEngine cut shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub cut shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Barrington Research increased their price target on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. Finally, SunTrust Banks, Inc. upgraded shares of BioScrip from a “hold” rating to a “buy” rating and increased their price target for the company from $3.25 to $3.75 in a report on Thursday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.75.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.